Photo by: Jacopo188, via Wikimedia Commons
Researchers from Brigham and Women’s Hospital in Boston and the Harvard Stem Cell Institute in Cambridge, Mass., have identified a novel pathway that may explain why skin thickens in psoriasis, and could lead to new strategies for developing therapies for the condition.
The findings are published online ahead of print in the Journal of Investigative Dermatology (Dec. 11, 2019).
“Psoriasis places social and psychological stress on patients and is associated with risk of diabetes, cardiovascular disease and more. While steroids and biologics can be prescribed, we don't have a cure because we haven't understood the cause,” said co-senior author Dr. George Murphy in a press release. Dr. Murphy is director of the program in dermatopathology in the department of pathology at the Brigham.
“Our initial finding that skin thickening in psoriasis is due to build-up of dysregulated stem cells and their progeny are exciting because it represents a new way of thinking about an old and significant skin disease.”
To better understand the basis for the dysregulated skin stem cell behaviour, the investigators looked at the epigenome, the methylated wrapping that covers each DNA strand and orchestrates how individual genes behave.
“Without understanding the mechanism underlying a disease, it’s hard to find effective treatments,” said co-senior author Dr. Christine Lian, a dermatopathologist in the department of pathology at the Brigham. “The question we decided to pursue was: Is there an epigenetic abnormality in psoriasis that may explain why stem cells are misbehaving?”
The investigators identified a defect in the epigenetic covering that resulted in the loss of a DNA methylation hydroxymethylation mark. Known as loss of 5-hmC, this defect was found in cells from patients with psoriasis but not other skin conditions that produce a similar skin thickening, such as callous-like areas from chronic irritation. The team replicated the defect in a mouse model of psoriasis and found that it preferentially affected genes that regulated the function of skin cells.
Drs. Lian and Murphy had previously shown that 5-hmC loss in the skin epigenome can be reprogrammed using agents as fundamental as ascorbic acid. Reasoning that therapeutic correction of the epigenomic defect in psoriasis might reverse the entire process, they conducted some experiments in cell culture. Early data from those experiments suggests that 5-hmC levels can be restored to correct the deficiency seen in psoriasis, according to the release.
The investigators note that while there is much interest in the role of vitamin C, additional research is needed to develop and test effective treatments since simply taking a vitamin supplement is likely to have little effect. The team has begun work on the next research steps, which will involve three-dimensional bioprinting of skin stem cells in the context of their supportive niches to test other epigenetic reprogramming agents.
“If successful, our epigenetic stem cell explanation for psoriasis hopefully could transform therapy, allowing for more personalized and targeted approaches directed at the very cells that accumulate to form the heartbreak of this all-too-often devastating skin condition,” said Dr. Murphy.